# 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

> **NCT00339196** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 25 (actual)

## Conditions studied

- Acute Myelogenous Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** 5 azacytidine - VALPROIC acid- Retinoic acid

## Key facts

- **NCT ID:** NCT00339196
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00339196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00339196, "5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00339196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*